Objective: To elucidate the changes in interleukin-6 (IL-6) levels in whole saliva during the treatment phase in patients with oral squamous cell carcinoma (OSCC).
Introduction
The number of patients with oral cancer is increasing gradually (especially in younger people). 1 Although the diagnostic modalities and therapeutic management of oral cancer is improving, the treatment outcome and prognosis of oral cancer have improved little. 2 The overall 5-year survival rates for oral cancer have remained low at ~30 to 50%. 3 Some researchers pointed out the imperative need for a sensitive biomarker to improve early detection of oral cancer. [1] [2] [3] [4] Circulatory tumor markers for oral squamous cell carcinoma (OSCC) were investigated in various studies and showed relatively moderate sensitivity and specificity values with relation to diagnosis, prognosis predicting, or treatment monitoring. [1] [2] [3] [4] [5] [6] Saliva has many advantages as a sample over both serum and tissues. 7 Saliva is relatively easy to collect in sufficient quantities for analysis even in the small clinic or the laboratory.
It is recognized that numerous cytokines have various roles in the diseases of the oral mucosa. 8, 9 Interleukin-6 (IL-6) is a multifunctional cytokine that participates in the inflammatory and immune responses. [10] [11] [12] Proinflammatory cytokines, such as IL-6, have been shown to directly promote the growth of certain types of cancer, and is associated with increased the rate of metastasis. 2, 13 However, IL-6 has dual effects, inhibiting the growth of some cells while stimulating the growth of others. 14 IL-6 is currently being assessed for its ability to promote or inhibit various types of tumors.
2, 4, 9 Some previous studies indicated that the concentrations of IL-6 in serum and saliva are significantly elevated in patients with oral neoplastic and preneoplastic lesions as compared with controls. 8, 9, [15] [16] [17] [18] Rhodus et al. 9 reported that OSCC as well as oral preneoplastic lesions had significantly higher salivary levels of IL-6 than controls. They suggested that the progression of OSCC may be enhanced by the continued expression of the proinflammatory cytokines. St. John et al. 2 examined IL-6 at the messenger RNA (mRNA) and protein levels in both the serum and unstimulated saliva of OSCC patients and age-and gender-matched controls. They demonstrated that IL-6 at both the mRNA and protein levels was detected in higher concentrations in the serum of patients with OSCC compared with controls. However, they did not find significant differences in the salivary concentrations of IL-6 between the two groups at either the mRNA or the protein level. Some researchers suggested that IL-6 in saliva and serum may be a useful biomarker for patient screening. 2, 9, 18 However, the clinical significance of IL-6 in saliva in patients with OSCC is not clearly understood. Since previous studies reported only baseline salivary IL-6 concentrations, 2, 9, 15, 18 it is also uncertain whether IL-6 in saliva would change depending on the various treatment phases. If the concentrations of IL-6 in saliva change during the treatment phase, we have to be concerned about appropriate time to collect saliva samples. Here, however, we do not know when we can collect valuable saliva for early detection or predicting the prognosis of OSCC. We hypothesized that the elevated levels of IL-6 in saliva dropped rapidly after treatment in patients with OSCC. This information may enable the choice of an appropriate time to collect saliva samples in evaluating patient's condition.
This preliminary study was performed to elucidate the changes in IL-6 levels in saliva during the treatment phase in patients with OSCC, and the correlations between IL-6 and clinical factors.
Materials and Methods

Patients
A total of 29 consecutive subjects (11 women and 18 men) with histologically proven OSCC were enrolled in this prospective study ( Table   1 ). All of the subjects were hospitalized for examination and treatment. Nineteen healthy age-matched volunteers (10 women and 9 men) were also recruited as controls. The control subjects ranged in age from 41 to 92 years, with a mean age of 67 years ( Table 2 ). All of the patients and controls were Japanese (single race). There was no significant difference between the patients and control groups in terms of gender (chi-square: 1.0).
None of these patients and controls had a history of autoimmune diseases and hepatitis.
Although 12 of the patients were smokers, none of the patients smoked during the period of hospitalization (Table 1) . Only five controls smoked.
Twenty-five (86%) and thirteen (68%) cases of the patient and the control groups have been taking medicine regularly because of the systemic diseases, such as hypertension, heart disease, diabetes and cerebrovascular disorders.
All of the participants, including the healthy volunteers, gave their informed consent to collection of saliva for the purpose of the study. This study was approved by the Institutional Review Boards of Hokkaido University, Graduate School of Dental Medicine (2006).
Periodontal disease
We divided the patients into two groups according to the presence or absence of periodontal diseases according to periodontal status (CPI) by WHO. 8, 20 In the present study, 10 patients (34%) and 7 controls (37%)
were defined as having periodontal disease (Table 1 and 2).
Stimulated saliva sample preparation
All samples of stimulated saliva were collected using a commercially available device (Salivette®; Sarstedt Ltd, Leicester, UK), which has been used for salivary analyses in many previous studies. [21] [22] [23] All of the patients and controls were instructed not to eat for one hour prior to sampling.
Saliva samples were obtained before lunch, between 10:00 and 12:00, in accordance with the method of Menon. 23 Saliva samples were collected by chewing the Salivette® cotton for 1 min, and depositing the cotton into the collection tube provided. The collection tubes were immediately centrifuged at 2 000 rpm (800 g) for 10 min to obtain whole saliva and stored at -80°C until assay.
Saliva was collected three times in the patient group: just after hospitalization (period 1), just before main treatment (i.e., surgery, radiation and/or chemotherapy)(period 2), and at the time of discharge (period 3). The mean interval between periods 1 and 2 was 11±8 days, while that between periods 2 and 3 was 30±18 days. The volume of saliva ranged 0.3-2.6 mL (mean: 1.8 mL). Samples less than 0.5 mL in volume or those that contained an excessive amount of blood were excluded from the study. Five samples each obtained during periods 2 and 3 were excluded. In the period 2, three and two samples were excluded because of shortage of volume and mixing of blood, respectively.
In the period 3, four and one samples were excluded because of shortage of volume and mixing of blood, respectively. We needed more than 0.5 mL in volume of saliva to measure IL-6 levels in this study. The samples available for assay were from 29 cases in period 1 and 24 cases in each of periods 2 and period 3.
Blood tests for C-reactive protein (CRP) were performed on the patients at the time of hospitalization (period 1). All of these assay were performed in our hospital laboratory by particle enhanced turbimetric immunoassay with a high sensitivity CRP flex reagent cartridge (normal range: 0-0.3 mg/dL).
Measurement of IL-6 concentrations.
IL-6 concentrations were measured by a highly sensitive chemiluminescent enzyme immunoassay (CL-EIA) in duplicate analyses using mouse monoclonal antibodies against recombinant IL-6 (Fujirebio Inc., Tokyo, Japan). 25 The intra-day and inter-day coefficients of variation (CV) of this assay were 1.5-5.5% and 3. There were no significant differences in IL-6 concentrations (period 1)
between the smokers and non-smokers (p=0.48) or between patients with and without periodontal disease (p=0.37). There was no significant correlation between IL-6 concentration in period 1 and serum CRP (p=0.08). L-6 concentrations were not influenced by the provision of a biopsy or no biopsy (Table 3) . Pre-operative chemotherapy did not influence the salivary IL-6 concentrations significantly (case 28).
Discussion
To our knowledge, there have been no previous studies of the changes in the levels of IL-6 in saliva during the treatment phase in patients with OSCC. In the present study, the concentration of IL-6 in stimulated saliva in patients with OSCC was significantly higher than that in controls, and
was not reduced to the levels of controls at discharge (post-treatment days:
30±18 days). These findings may suggest that OSCC patients produce increased release of IL-6 into saliva and that IL-6 contributes to carcinogenesis of oral mucosa and maintenance of condition with OSCC. It is believed that proinflammatory cytokines play an important role in carcinogenesis. 8, 26, 27 and IL-6 inactivates p53 tumor suppressor gene. after treatment. 12, 31 We cannot compare these results with ours due to different patient characteristics. However, we cannot deny the possibility that the salivary concentrations of IL-6 might have come down to the levels of controls, if we had collected saliva from the OSCC patients at the time of 2-3 months after treatment. A fourth possibility is that salivary IL-6 concentrations may remain elevated in patients predisposed to tumor recurrences. At this time, however, this cannot be determined. The fifth possibility is that the elevated IL-6 levels after treatment may be due to the enrichment of saliva caused by the dry mouth symptoms associated with cancer treatment. To avoid the influence of saliva enrichment, we excluded saliva samples with volumes of less than 0.5 mL in the present study.
However, only this consideration may be insufficient to avoid the influence of enrichment of saliva. However, recent study demonstrated an interesting result. Boras et al. 32 stated that xerostomia as a result of drug intake did not alter IL-6 levels in saliva.
In previous two studies, mean IL-6 concentrations before treatment, as determined by ELISA, in unstimulated saliva from 13 and 19 patients with OSCC, has been reported to be 88.2±43.2 pg/mL and 86.5±84.7 pg/mL, respectively, 17, 18 higher than the concentrations we measured in stimulated saliva during periods 1 and 2. These findings suggest that our saliva samples may have been diluted. On the contrary, stimulation with chewing the cotton might activate the release of IL-6 from the tumor and gingiva. In our patients with OSCC, we think it was pretty difficult to collect enough volume of unstimulated saliva in a short time. As we collected saliva from the patients three times, we would like to ease the burden of the patients.
However, since we collected stimulated saliva three times by the same manner, we think our comparisons are valid.
It is clear that the majority of IL-6 in saliva comes from the local region.
Tumor size (T-stage) has been reported to be an independent predictor of survival in patients with OSCC. 14 12 suggested that IL-6 was produced by SCC, and contributed to the progression of the disease. We could not measure the serum levels of IL-6 in the patients and controls in the present study. St. John et al. 2 reported the mean concentrations of IL-6 in the serum were 86.5 pg/mL and 0 pg/mL, in patients with OSCC and healthy controls, respectively. Sun et al. 12 reported that the mean serum levels of IL-6 were 3.4±3.1 pg/mL and 2.0±1.5 pg/mL in patients with erosive oral lichen planus and healthy subjects, respectively. From the results of the previous and present studies, it is natural that IL-6 in saliva was produced by not only cancer cells but also peripheral circulation. Moreover, in local environments, the secretion of IL-6 may depend on not only on cancer cells but also on inflammatory reactions.
A variety of factors may influence the physiological characteristics of whole saliva, including time of collection, meals, medication use, periodontal inflammation, smoking or physical activity. 33, 34 In the present study, all of the patients were inpatients. All of the patients and controls
were instructed not to eat one hour prior to the sampling. 23 Saliva samples were obtained before lunch, between 10:00 and 12:00, to reduce the influence of meals, exercise, and circadian rhythms. There were no obvious correlations between the levels of IL-6 and the presence of periodontal disease in the present study. In accordance with a report of Rhodus et al., 9 we felt it appropriate to exclude subjects taking drugs that induce hyposalivation, such as anticholinergic, antihistamine, and antihypertensives agents. In the present study, however, most patients were elderly, and it was not possible to exclude patients taking drugs associated with hyposalivation, as the most (25 cases) were taking such drugs routinely. Recently, an interesting finding was reported that there was no significant correlation between levels of salivary IL-6 and number of medications taken in patients with drug-induced xerostomia. 32 In conclusion, the concentration of IL-6 in whole saliva in patients with OSCC was significantly higher than that in controls. The concentration of IL-6 changed during the treatment period, and returned to baseline levels at discharge (post-treatment days: 30±18 days). We intend to continue our research efforts to determine whether the continuous elevation of IL-6 in saliva would influence the prognosis of OSCC.
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